Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer

Published:2014-11-17 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Yang Zu-Yao¹,Liu Li¹,Mao Chen¹,Wu Xin-Yin¹,Huang Ya-Fang¹,Hu Xue-Feng¹,Tang Jin-Ling¹

Affiliation:

1. The Chinese University of Hong Kong; Division of Epidemiology, The Jockey Club School of Public Health and Primary Care; Hong Kong SAR China

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD009948.pub2/fullpdf

Reference58 articles.

1. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer;Butts;Journal of Clinical Oncology,2007

2. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099;Lynch;Journal of Clinical Oncology,2010

3. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial;Pirker;The Lancet,2009

4. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer;Rosell;Annals of Oncology,2008

5. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin;Baselga;Journal of Clinical Oncology,2000

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plexin domain-containing 1 may be a biomarker of poor prognosis in hepatocellular carcinoma patients, may mediate immune evasion;World Journal of Gastrointestinal Oncology;2024-05-15

2. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01

3. Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune response in liver cancer;Journal of Cancer Research and Clinical Oncology;2023-12

4. Diabetic neuropathy: Pathogenesis and evolving principles of management;Disease-a-Month;2023-09

5. Efficacy of combined PD-1 immune therapy and chemotherapy in the treatment of locally advanced nonsmall cell lung cancer;Tropical Journal of Pharmaceutical Research;2023-06-06